Eli Lilly and Company (NYSE:LLY) Shares Acquired by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 8.9% during the third quarter, HoldingsChannel reports. The fund owned 42,122 shares of the company’s stock after acquiring an additional 3,452 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Eli Lilly and Company were worth $22,625,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Eli Lilly and Company by 1.9% during the 2nd quarter. State Street Corp now owns 33,878,417 shares of the company’s stock valued at $15,888,300,000 after acquiring an additional 642,274 shares during the last quarter. Geode Capital Management LLC boosted its stake in Eli Lilly and Company by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock valued at $7,111,568,000 after acquiring an additional 338,077 shares during the last quarter. Morgan Stanley boosted its stake in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after acquiring an additional 3,691,436 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $3,416,206,000. Finally, Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 10.7% during the second quarter. Capital Research Global Investors now owns 6,782,977 shares of the company’s stock worth $3,181,061,000 after purchasing an additional 654,026 shares during the period. 81.38% of the stock is currently owned by institutional investors.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 34,538 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the transaction, the insider now directly owns 99,719,884 shares of the company’s stock, valued at $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LLY. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. Truist Financial reissued a “buy” rating and set a $650.00 target price on shares of Eli Lilly and Company in a report on Wednesday, November 29th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $727.00 to $822.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. TheStreet cut shares of Eli Lilly and Company from a “b” rating to a “c+” rating in a report on Monday, December 4th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Eli Lilly and Company in a report on Thursday, November 9th. They issued a “hold” rating and a $535.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $589.90.

Check Out Our Latest Analysis on LLY

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $40.10 during trading hours on Monday, hitting $707.75. 2,186,619 shares of the company’s stock traded hands, compared to its average volume of 2,874,289. Eli Lilly and Company has a 52 week low of $309.20 and a 52 week high of $711.30. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05. The company’s fifty day simple moving average is $606.79 and its two-hundred day simple moving average is $572.66. The company has a market cap of $671.87 billion, a price-to-earnings ratio of 127.65, a price-to-earnings-growth ratio of 2.16 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The company had revenue of $9.50 billion during the quarter, compared to analyst estimates of $8.88 billion. As a group, equities analysts anticipate that Eli Lilly and Company will post 6.34 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 4th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.30 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.20 annualized dividend and a dividend yield of 0.73%. Eli Lilly and Company’s dividend payout ratio (DPR) is 81.88%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.